Results 61 to 70 of about 923 (130)

Azvudine exhibits potent differentiation-inducing effect by targeting the TERT/p21 axis in acute myeloid leukemia.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
C. Kwon, Ji-Eun Lee, Byeol Jeon, Tae-Jin Kim, Sang-Hun Lee, Ho-Jin Shin, Sang-Woo Kim   +6 more
semanticscholar   +2 more sources

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety.Methods: We conducted a retrospective cohort study involving
An-Hua Wei, Lu Zeng, Lu Wang, Lin Gui, Wen-Ting Zhang, Xue-Peng Gong, Juan Li, Dong Liu   +7 more
doaj   +1 more source

Clinical Characteristics of SARS-COV-2 Omicron Variant in Acute Myeloid Leukemia and Acute Lymphocytic Leukemia Patients: A Multi-Center Retrospective Study. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background The death rate of hematological malignancies is high, and the death rate of patients with COVID‐19 infection is further increased. Although there have been expert consensus and relevant guidelines to introduce the recommendations of the guidelines for patients with hematological malignancies complicated with COVID‐19 infection ...
Wang L, Mi R, Chen L, Liu J, Yang H, Hu M, Xiaoqiang Z, Zhang Y, Xu X, Liu B, Zhao H, Qianyu L, Liu T, Zhenzhu C, Yao J, Yang Y, Wei X.   +16 more
europepmc   +2 more sources

Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals. [PDF]

Influenza Other Respir Viruses
ABSTRACT Introduction There is still a lack of clinical evidence comprehensively evaluating the effectiveness of antiviral treatments for COVID‐19 hospitalized patients. Methods A retrospective cohort study was conducted at Beijing You'An Hospital, focusing on patients treated with nirmatrelvir/ritonavir or azvudine.
Gao Y, Dong Y, Bu Q, Gong Z, Wang W, Zhou Z, Gao Y, Liu L, Wu M, Zhang J, Liang L, Li H, Jiang M, Luo Z, Ma Y, Zhang X, Hu Z.   +16 more
europepmc   +2 more sources

Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies. [PDF]

Clinics (Sao Paulo)
Zeng Z, Li F, Zhong M, Zhu L, Chen W, Wang X.   +5 more
europepmc   +2 more sources

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, Yin Ying, Jun Zhu, Cheng Fei, Junlei Xiang, Lingli Shen, Qiliang Luo, Yinhuan Wu, Ayiguzhali Wusiman, Chuanwei Xin, Meiling Zhang, Gonghua Li, Xiang Li   +17 more
doaj   +1 more source

Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy

Journal of Medical Virology, Volume 97, Issue 5, May 2025.
ABSTRACT Nirmatrelvir‐ritonavir (NMV‐r) has been widely used to treat coronavirus disease 2019 (COVID‐19) for a standard period of 5‐days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity after the standard 5‐day course of NMV‐r treatment.
Huqin Yang, Leyi Gao, Yi Xue, Zhijin Zhang, Lujia Guan, Haifan Zhang, Haomiao Ma, Xuyan Li, Jieqiong Li, Zhaohui Tong   +9 more
wiley   +1 more source

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This is the first study comparing the effectiveness of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in treating moderate and severe COVID‐19 patients. Patients who received simnotrelvir/ritonavir exhibited shorter hospitalization. Disease progression, viral clearance times, and symptom resolution time were similar between the two groups.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
wiley   +1 more source

Selectively T cell phosphorylation activation of azvudine in the thymus tissue with immune protection effect

Acta Pharmaceutica Sinica B
Thymus is the important immune organ, responsible for T cell development and differentiation. The lower circulating T counts have been observed in patients who died from COVID-19 compared with survivors. Azvudine, also known as FNC, is a thymus-homing anti-SARS-CoV-2 drug in treating COVID-19 patients.
Ning Sheng, Rui Li, Yang Li, Zhe Wang, Lulu Wang, Yuhuan Li, Jinlan Zhang, Jiandong Jiang   +7 more
semanticscholar   +4 more sources

Clinical characteristics, diagnosis and short‐term outcomes of COVID‐19–associated acute myocarditis in China

ESC Heart Failure, Volume 12, Issue 1, Page 338-352, February 2025.
Abstract Aims Acute myocarditis (AM) has been recognized as a rare complication of coronavirus disease 2019 (COVID‐19) infection. This study was conducted to present the clinical characteristics, disease courses and short‐term prognoses of Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) induced AM in China, which has ...
Huihui Liu, Ping Zhou, Yan Huang, Sulan Yan, Lei Zhou, Chuanyu Gao, Lian Wang, Jianjun Tang, Qiong Zhou, Xinqing Li, Xiaofeng Zhuang, Mei Zhai, Liyan Huang, Xuemei Zhao, Barry Greenberg, David H. Hsi, Yuhui Zhang, Jian Zhang   +17 more
wiley   +1 more source